Gossamer Bio is a clinical-stage biopharmaceutical company headquartered in San Diego, California, that focuses on developing therapeutics for pulmonary arterial hypertension (PAH). The company's primary asset is GB002, an inhaled small molecule inhibitor targeting platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor, and c-KIT. GB002 is currently in Phase 3 clinical development for PAH treatment. The company operates under a license agreement with Pulmokine, Inc., which grants rights to develop and commercialize GB002 and related backup compounds.
As a clinical-stage company, Gossamer Bio has not yet generated revenue from product commercialization. The company operates with a workforce of 144 full-time employees and is based in San Diego. The company was incorporated in Delaware in 2015 and trades on the Nasdaq under the ticker GOSS.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.25 | $-0.25 | +78.8% | |
| 2023 | $-1.18 | $-1.18 | +56.5% | |
| 2022 | $-2.71 | $-2.71 | +13.4% | |
| 2021 | $-3.13 | $-3.13 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-13 | 0001728117-25-000021 | SEC ↗ |
| 2023-12-31 | 2024-03-05 | 0001728117-24-000019 | SEC ↗ |
| 2022-12-31 | 2023-03-17 | 0001728117-23-000010 | SEC ↗ |
| 2021-12-31 | 2022-03-03 | 0001728117-22-000019 | SEC ↗ |
| 2020-12-31 | 2021-02-26 | 0001728117-21-000019 | SEC ↗ |
| 2019-12-31 | 2020-03-24 | 0001564590-20-012323 | SEC ↗ |
| 2018-12-31 | 2019-03-22 | 0001564590-19-009031 | SEC ↗ |